Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study.

Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study. Abstract Text:

Forty-one patients with refractory acute non-lymphocytic leukemia (ANLL) in relapse were treated with 13-cis-retinoic acid (cRA) as salvage therapy. The cRA was given as a single oral dose of 100 mg/m2/day for 4 weeks. One patient achieved a complete remission and two patients achieved a partial remission with reduction of the bone marrow blast count from 40 to 20% after the first course. We recommend further study of cRA in combination with other agents in the treatment of ANLL in children.

Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study. Publishing Authors By Initials

For similar cells: cells, cultured: tumor cells, cultured research abstracts see: cells: cells, cultured: tumor cells, cultured research

PUBMED ID PMID:

MEDLINE DATE:

Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of immunotherapy : official journal of the

VOLUME: 10

Page Numbers: 77-83

Journal Abbreviation: J. Immunother.

ISSN: 1053-8550

DAY: 18

MONTH: Apr

YEAR: 1991

Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9102704

Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study. Keywords Mesh Terms:

KEYWORDS: Tumor Cells, Cultured

MESH TERMS: pathology

Chemical & Substance for Abstract: Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study. Information

Substance Name: Isotretinoin

Registry Number: 4759-48-2

Grant and Affiliation Information for Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study.

AFFILIATION: Division of Pediatric Hematology/Oncology, Emory University, Atlanta, Georgia 30322.

Country: UNITED STATES

AGENCY: United States NCI

GRANT: CA-32278

ACRONYM: CA

MEDLINETA: J Immunother (1991)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study Related Publications

• Circulatory dynamics in cholera; their mechanism and prognostic significance.
• Combined chemotherapy in childhood rhabdomyosarcoma.
• Experimental ocular schistosomiasis.
• Observations on the isolated gut of the mosquito.
• Phase II study of 13-cis-retinoic acid in pediatric patients with acute nonlymphocytic leukemia--a Pediatric Oncology Group study.
• Study of factor VII, tissue factor pathway inhibitor and monocyte tissue factor in noninsulin-dependent diabetes mellitus.
• [Enzyme system which reduces 1-dehydroascorbic acid.]
• [Enzyme system which reduces I-dehydroascorbic acid. II.]
• [True trigeminal neuralgia. Increased cholesterol and triglycerides in blood as an etiologic factor?]